Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scimed/Cardiovascular Dynamics

This article was originally published in The Gray Sheet

Executive Summary

Enter pact under which Scimed obtains an exclusive license to patents used in the manufacture of Endosonics subsidiary CVD's Transport angioplasty/drug delivery catheter in the cardiovascular market. CVD retains rights to the technology for other markets such as peripheral and neurovascular. Minneapolis-based Scimed will make an undisclosed equity investment in CVD in exchange for the patent rights, as well as "incremental" product development funding and royalty payments on product sales. The companies "will collaborate on research and development programs to further develop" the technology, CVD says. CVD retains sole marketing rights for the technology in all other markets, as well as all rights to its Bullett drug delivery catheter and its other angioplasty technologies



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts